Echinocandin Failure Case Due to a Previously UnreportedFKS1Mutation in Candida krusei

Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates

(2014) Gregory A. Eschenauer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Technical Note onCandidaand micafungin, anidulafungin and fluconazole

(2014) Maiken Cavling Arendrup et al.   MYCOSES

Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure

(2013) James S. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin

(2013) A. Fekkar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme

(2013) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside

(2013) M. Cuenca-Estrella   CLINICAL MICROBIOLOGY AND INFECTION

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of theFKS2Gene Developed after Prolonged Therapy with Caspofungin

(2012) María Teresa Durán-Valle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in Candida tropicalis

(2012) Rasmus Hare Jensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*

(2012) Maiken C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

The changing epidemiology of healthcare-associated candidemia over three decades

(2012) Daniel Diekema et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Echinocandin resistance in human pathogenic fungi

(2012) Carol A Munro   Expert Review of Anti-Infective Therapy

New Fks Hot Spot for Acquired Echinocandin Resistance inSaccharomyces cerevisiaeand Its Contribution to Intrinsic Resistance ofScedosporiumSpecies

(2011) Michael E. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients

(2010) Olivier Lortholary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity

(2010) K. Niimi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Antifungal drug resistance: do molecular methods provide a way forward?

(2009) David S Perlin   CURRENT OPINION IN INFECTIOUS DISEASES

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

(2009) Hsin-Yun Sun et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

(2008) M. Desnos-Ollivier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY